A Double-blind, Placebo-controlled, Randomized Study of Vortioxetine Treatment on Major Depression, Cognition, and Systemic Inflammatory Biomarkers Associated With Depression and Cancer Progression in Women With Breast Cancer

Trial Profile

A Double-blind, Placebo-controlled, Randomized Study of Vortioxetine Treatment on Major Depression, Cognition, and Systemic Inflammatory Biomarkers Associated With Depression and Cancer Progression in Women With Breast Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Vortioxetine (Primary)
  • Indications Bipolar depression; Breast cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 29 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 24 Jun 2016 Planned End Date changed from 1 Jan 2019 to 1 Jul 2019.
    • 24 Jun 2016 Planned primary completion date changed from 1 Jan 2018 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top